Incidence and predictors of hemodynamic compromise due to high-grade AV block after TAVI.
AV block
TAVI
cardiac arrest
cardiac resuscitation
pacemaker
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
02
2023
accepted:
24
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
High-grade AV block (HAVB) is the most frequent adverse event after transcatheter aortic valve implantation (TAVI). In rare cases, HAVB is associated with hemodynamic compromise (HC) followed by syncope or application of cardiopulmonary resuscitation (CPR), but data on this severe complication are scarce. The aim of the present study was to investigate the incidence and predictors of HC due to HAVB in patients undergoing TAVI. In this retrospective analysis of 4,602 TAVI cases between 2010 and 2022, 466 developed HAVB. Baseline characteristics and procedural and postprocedural findings were compared for patients with HC versus those without. Univariate and multivariable regression analyses were used to investigate independent predictors of HC. Forty-nine of 466 patients (10.5%) had HC due to HAVB after TAVI. Patients with HC had a longer hospital stay [10 (8-13) vs. 13 (9-18) days; HC due to HAVB after TAVI occurred in over 10% of cases. Development of post-TAVI delirium and contrast agent volume are independent predictors of this severe complication.
Sections du résumé
Background
UNASSIGNED
High-grade AV block (HAVB) is the most frequent adverse event after transcatheter aortic valve implantation (TAVI). In rare cases, HAVB is associated with hemodynamic compromise (HC) followed by syncope or application of cardiopulmonary resuscitation (CPR), but data on this severe complication are scarce. The aim of the present study was to investigate the incidence and predictors of HC due to HAVB in patients undergoing TAVI.
Methods
UNASSIGNED
In this retrospective analysis of 4,602 TAVI cases between 2010 and 2022, 466 developed HAVB. Baseline characteristics and procedural and postprocedural findings were compared for patients with HC versus those without. Univariate and multivariable regression analyses were used to investigate independent predictors of HC.
Results
UNASSIGNED
Forty-nine of 466 patients (10.5%) had HC due to HAVB after TAVI. Patients with HC had a longer hospital stay [10 (8-13) vs. 13 (9-18) days;
Conclusion
UNASSIGNED
HC due to HAVB after TAVI occurred in over 10% of cases. Development of post-TAVI delirium and contrast agent volume are independent predictors of this severe complication.
Identifiants
pubmed: 37346284
doi: 10.3389/fcvm.2023.1161871
pmc: PMC10280067
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1161871Informations de copyright
© 2023 Weferling, Lan Cheong Wah, Fischer-Rasokat, Hain, Renker, Charitos, Liebetrau, Treiber, Choi, Hamm and Kim.
Déclaration de conflit d'intérêts
CH contributes to the advisory board of Medtronic, and W-KK received proctor/speaker honoraria from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1218-1228
pubmed: 26292585
Europace. 2022 Jul 21;24(7):1127-1136
pubmed: 35138367
Clin Res Cardiol. 2015 Aug;104(8):632-9
pubmed: 25720330
JACC Cardiovasc Interv. 2022 Mar 28;15(6):575-589
pubmed: 35331449
Clin Res Cardiol. 2018 Jan;107(1):60-69
pubmed: 28963581
Age Ageing. 2020 Apr 27;49(3):389-394
pubmed: 32091096
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
Am J Cardiol. 2018 Dec 1;122(11):1917-1923
pubmed: 30293651
Circulation. 2002 Dec 10;106(24):3006-8
pubmed: 12473543
JACC Cardiovasc Interv. 2018 Jan 22;11(2):160-168
pubmed: 29348010
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):60-9
pubmed: 25616819
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
JACC Cardiovasc Interv. 2020 Jan 27;13(2):170-179
pubmed: 31973793
Circ Cardiovasc Interv. 2021 Sep;14(9):e010543
pubmed: 34433290
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Am J Physiol. 1990 Aug;259(2 Pt 2):H300-8
pubmed: 2386214
JACC Cardiovasc Interv. 2022 Mar 28;15(6):590-598
pubmed: 35331450
Front Surg. 2022 Jul 26;9:937293
pubmed: 35959124
JACC Cardiovasc Interv. 2018 Feb 12;11(3):301-310
pubmed: 29413244
Am J Cardiol. 2015 Apr 15;115(8):1116-22
pubmed: 25726383
BMJ Open. 2016 Oct 5;6(10):e012683
pubmed: 27707832
Catheter Cardiovasc Interv. 2021 Apr 1;97(5):940-947
pubmed: 33382519
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Circ Cardiovasc Interv. 2016 May;9(5):e003635
pubmed: 27169577
EuroIntervention. 2020 Feb 20;15(14):1240-1247
pubmed: 31763985
Catheter Cardiovasc Interv. 2015 Mar;85(4):648-54
pubmed: 25413312
Medicina (Kaunas). 2021 Jul 07;57(7):
pubmed: 34356976
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1721-1729
pubmed: 29803694
Circ Cardiovasc Qual Outcomes. 2016 May;9(3):312-21
pubmed: 27116975
Biomed Res Int. 2013;2013:323491
pubmed: 24102052
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1286-1291
pubmed: 27566989
JACC Cardiovasc Interv. 2022 Dec 12;15(23):2398-2407
pubmed: 36121242
J Am Coll Cardiol. 2004 Nov 2;44(9):1883-8
pubmed: 15519023
J Am Coll Cardiol. 2004 Oct 19;44(8):1619-25
pubmed: 15489094
J Am Coll Cardiol. 2014 Jul 15;64(2):129-40
pubmed: 25011716
J Thorac Cardiovasc Surg. 2016 Mar;151(3):815-823.e2
pubmed: 26774165